Research Analysts Set Expectations for APLS Q4 Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Equities researchers at William Blair reduced their Q4 2026 earnings per share (EPS) estimates for shares of Apellis Pharmaceuticals in a note issued to investors on Tuesday, July 1st. William Blair analyst L. Hanbury-Brown now expects that the company will earn $0.00 per share for the quarter, down from their prior estimate of $0.04. The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.38). The company had revenue of $149.90 million for the quarter, compared to the consensus estimate of $197.61 million. Apellis Pharmaceuticals had a negative return on equity of 99.19% and a negative net margin of 28.83%. Apellis Pharmaceuticals's quarterly revenue was down 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.54) earnings per share.

Other research analysts have also issued reports about the stock. Mizuho reduced their target price on shares of Apellis Pharmaceuticals from $30.00 to $20.00 and set a "neutral" rating for the company in a research note on Wednesday, May 14th. Morgan Stanley boosted their price target on Apellis Pharmaceuticals from $25.00 to $26.00 and gave the stock an "equal weight" rating in a research report on Wednesday. Robert W. Baird decreased their price objective on shares of Apellis Pharmaceuticals from $55.00 to $47.00 and set an "outperform" rating for the company in a report on Thursday, May 8th. Raymond James Financial lowered Apellis Pharmaceuticals from a "strong-buy" rating to an "outperform" rating and cut their price objective for the company from $75.00 to $52.00 in a report on Friday, May 9th. Finally, Citigroup lowered their target price on Apellis Pharmaceuticals from $49.00 to $41.00 and set a "buy" rating on the stock in a report on Thursday, May 22nd. Nine investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $39.79.

Apellis Pharmaceuticals Stock Performance

Shares of Apellis Pharmaceuticals stock traded up $0.17 during trading on Thursday, hitting $17.99. 891,120 shares of the stock were exchanged, compared to its average volume of 2,347,184. The company has a debt-to-equity ratio of 2.76, a quick ratio of 3.62 and a current ratio of 4.08. Apellis Pharmaceuticals has a 12 month low of $16.10 and a 12 month high of $42.47. The stock's fifty day moving average is $18.14 and its 200 day moving average is $23.70. The stock has a market cap of $2.26 billion, a PE ratio of -10.05 and a beta of 0.67.

Insiders Place Their Bets

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 5,000 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $18.77, for a total transaction of $93,850.00. Following the completion of the sale, the general counsel directly owned 133,730 shares in the company, valued at approximately $2,510,112.10. This trade represents a 3.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 6.50% of the company's stock.

Institutional Trading of Apellis Pharmaceuticals

Several institutional investors have recently made changes to their positions in APLS. Teacher Retirement System of Texas boosted its stake in shares of Apellis Pharmaceuticals by 9.4% during the 4th quarter. Teacher Retirement System of Texas now owns 21,649 shares of the company's stock valued at $691,000 after buying an additional 1,864 shares during the period. Ameriprise Financial Inc. raised its holdings in shares of Apellis Pharmaceuticals by 2.6% during the fourth quarter. Ameriprise Financial Inc. now owns 882,801 shares of the company's stock worth $28,170,000 after acquiring an additional 22,507 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in Apellis Pharmaceuticals by 147.8% during the first quarter. Assenagon Asset Management S.A. now owns 74,325 shares of the company's stock valued at $1,625,000 after purchasing an additional 44,332 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Apellis Pharmaceuticals by 11.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 212,887 shares of the company's stock valued at $6,793,000 after purchasing an additional 21,822 shares in the last quarter. Finally, GAMMA Investing LLC increased its position in Apellis Pharmaceuticals by 1,795.4% in the 1st quarter. GAMMA Investing LLC now owns 10,235 shares of the company's stock worth $224,000 after purchasing an additional 9,695 shares during the last quarter. 96.29% of the stock is currently owned by institutional investors and hedge funds.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).